Slide 1: H1 and Q2 2026 Results
H1 and Q2 2026 Results Conference call and webcast for investors and analysts 27 July 2026
Slide 2: Cautionary statements regarding forward-looking statements
Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certai
Slide 3: Conference call agenda
H1 and Q2 2026 Results Conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Oncology Haematology Dave Fredrickson Susan Galbraith EVP, Oncology Haematology Business EVP, Oncology Haematology R&D BioPharmaceuticals R
Slide 4: CEO Opening Remarks
CEO Opening Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER 4
Slide 5: Commercial performance and pipeline delivery in H1 2026 drive confidence in $80bn Total Revenue ambition
Commercial performance and pipeline delivery in H1 2026 drive confidence in $80bn Total Revenue ambition +6% Total Revenue SUSTAINED COMMERCIAL +11% Total Revenue, ex. Farxiga and Brilinta1 MOMENTUM +11% Core EPS 6 positive key Phase III programme readouts MEANINGFUL sonesitatug efzimfotase PROGRESS
Slide 6: Growth driven by diverse sources of business and global presence
Growth driven by diverse sources of business and global presence +15% H1 2026 | % Product Revenue by therapy area -5% ID: 312 Oncology CVRM R&I ID Other Rare Disease Strength across R&I: +9% 46% 20% 16% 1% 2% 16% therapy areas 4,750 +11% H1 2026 | +6% Product Revenue ($m)1 CVRM: -12% 14,123 6,013 4,
Slide 7: Continued pipeline momentum in H1 2026
Continued pipeline momentum in H1 2026 KEY POSITIVE PHASE III PROGRAMME READOUTS NME NME NME OBERON / HICKORY / CLARITY- EMERALD-3 VOLGA TITANIA / CHESTNUT / I CAN Imfinzi + Imjudo Imfinzi ± Imjudo Gastric01 Ultomiris liver cancer bladder cancer sonesitatug vedotin MIRANDA MULBERRY IgAN gastric canc
Slide 8: Financial Results
Financial Results Aradhana Sarin CHIEF FINANCIAL OFFICER 8
Slide 9: H1 and Q2 2026 – Reported profit and loss
H1 and Q2 2026 – Reported profit and loss H1 2026 CER change % Total Q2 2026 CER change % Total $m % Revenue $m % Revenue - Product Sales 28,896 5 94 14,510 4 94 - Alliance Revenue 1,699 29 6 874 33 6 Product Revenue 30,595 6 100 15,384 5 100 - Collaboration Revenue 77 (9) - - n/m - Total Revenue 30
Slide 10: H1 and Q2 2026 – Core profit and loss
H1 and Q2 2026 – Core profit and loss H1 2026 CER change % Total Q2 2026 CER change % Total $m % Revenue $m % Revenue - Product Sales 28,896 5 94 14,510 4 94 - Alliance Revenue 1,699 29 6 874 33 6 Product Revenue 30,595 6 100 15,384 5 100 - Collaboration Revenue 77 (9) - - n/m - Total Revenue 30,672
Slide 11: FY 2026 guidance reiterated
FY 2026 guidance reiterated Capital allocation priorities remain unchanged Net debt/EBITDA 1.3x FY 2026 Guidance (CER) $bn Total Anticipated to increase by a mid-to-high single-digit 3.3 1.7 Revenue percentage 6.2 3.3 1.5 Anticipated to increase by a 23.4 26.9 Core EPS low double-digit percentage Ne
Slide 12: Oncology
Oncology Dave Fredrickson ONCOLOGY HAEMATOLOGY BUSINESS Susan Galbraith ONCOLOGY HAEMATOLOGY R&D 12
Slide 13: Oncology – H1 and Q2 2026
Oncology – H1 and Q2 2026 Total Revenue +15% in Q2 and H1 2026 driven by robust global demand across key medicines Oncology Q2 2026: key dynamics H1 2026 $14.1bn, +15% • Tagrisso +6%, extending 1L leadership with accelerating FLAURA2 uptake in 8,000 growing combo market 7,000 • Imfinzi +27%, Imjudo
Slide 14: Oncology – leadership in EGFRm lung cancer
Oncology – leadership in EGFRm lung cancer Commercial, BD and pipeline strength consolidate our position across EGFRm NSCLC Continued strong growth with Tagrisso globally Pipeline ensures continued leadership Establishing novel combinations in 2L+ FLAURA2 share of #1 3rd gen EGFR TKI prescribed glob
Slide 15: Oncology – Phase III data readouts transforming practice
Oncology – Phase III data readouts transforming practice Data readouts reinforce AstraZeneca potential in areas of high unmet need VOLGA | Imfinzi + EV +/- Imjudo reframing CLARITY-Gastric01 | sone-ve transforming outcomes with cisplatin-ineligible MIBC outcomes in 2L+ Claudin 18.2+ gastric cancer M
Slide 16: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber BIOPHARMACEUTICALS BUSINESS Sharon Barr BIOPHARMACEUTICALS R&D 16
Slide 17: BioPharmaceuticals – H1 and Q2 2026
BioPharmaceuticals – H1 and Q2 2026 Total Revenue -5% to $11.2bn; CVRM LoE impact largely offset by growth in R&I R&I CVRM Q2 2026: key dynamics H1 2026 $4.8bn, +9% H1 2026 $6.1bn, -12% 2,500 3,500 • Fasenra +13%, sustained IL-5 leadership in asthma, EGPA growth, ongoing China launch 3,000 • Breztri
Slide 18: BioPharmaceuticals – key pipeline developments in Q2 2026
BioPharmaceuticals – key pipeline developments in Q2 2026 Wainua | CARDIO-TTRansform Phase III trial elecoglipron | Phase IIb VISTA and SOLSTICE at ADA ATTR-CM trial in contemporary patient population Clinically meaningful efficacy 11.8% weight loss1 and 1.9% HbA1c reduction 2 Primary endpoint not m
Slide 19: Rare Disease
Rare Disease Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION 19
Slide 20: Rare Disease – H1 and Q2 2026
Rare Disease – H1 and Q2 2026 Total Revenue $4.9bn in H1 driven by continued patient demand across the portfolio Rare Disease Q2 2026: key dynamics H1 2026 $4.9bn, +11% 2,500 C5 Franchise • Ultomiris +12%, growth across indications, including within the 2,000 competitive gMG and PNH markets • Soliri
Slide 21: Rare Disease – Phase III presentations at congresses across rare disease indications
Rare Disease – Phase III presentations at congresses across rare disease indications Ultomiris | Expanding further into nephrology efzimfotase alfa | Transformative data for with I CAN Phase III trial paediatric HPP with MULBERRY and CHESTNUT reduction in proteinuria in IgAN 43% patients1 Clinically
Slide 22: CEO Closing Remarks
CEO Closing Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER 22
Slide 23: Continuing pipeline momentum with key Phase III readouts
Continuing pipeline momentum with key Phase III readouts H1 2026 H2 2026 H1 2027 H2 2027 EMERALD-3 | Imfinzi + Imjudo AVANZAR | Datroway + Imfinzi TROPION-Lung07 | Datroway TROPION-Breast03| Datroway + locoregional HCC 1L NSQ/NSQ TROP2+ NSCLC 1L NSQ/NSQ TROP2+ NSCLC Imfinzi post-neoadjuvant TNBC VOL
Slide 24: Strategically investing to deliver growth beyond 2030
Strategically investing to deliver growth beyond 2030 Significant progress across our transformative technologies in H1 2026 Weight ADCs and management Next-gen IO Cell therapy & radio- and CV risk bispecifics T-cell engagers conjugates factors Ongoing Phase III for AZD0120 in r/r First Phase III da
Slide 25: NMEs with pivotal data readouts before 2030 drive growth into the next decade
NMEs with pivotal data readouts before 2030 drive growth into the next decade >$5bn $3-5bn 1 sonesitatug vedotin2 AZD0120 Wholly-Owned ADCs2 balcinrenone + dapagliflozin saruparib zibotentan + dapagliflozin surovatamig elecoglipron | AZD6234 | AZD9550 cliramitug rilvegostomig laroprovstat franchise
Slide 26: Increasing confidence in Ambition 2030 and continued growth beyond
Increasing confidence in Ambition 2030 and continued growth beyond Continued commercial Advancing towards $80bn Investment in growth momentum in 2026 2030 Total Revenue ambition1 beyond 2030 Strong global demand Significant pipeline progress Strategic focus to fuel across medicines increases confide
Slide 27: Q&A Session
Q&A Session Pascal Soriot Aradhana Sarin CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER Marc Dunoyer Susan Galbraith CHIEF EXECUTIVE OFFICER, EVP, ONCOLOGY ALEXION HAEMATOLOGY R&D Dave Fredrickson Sharon Barr EVP, ONCOLOGY EVP, BIOPHARMACEUTICALS HAEMATOLOGY BUSINESS R&D Ruud Dobber Iskra Reic EVP,
Slide 28: Appendix
i ae} c 7) a. a. <
Slide 29: AstraZeneca P&L reference table
APPEN DI X | P&L definitions AstraZeneca P&L reference table P&L line-item definitions P&L line-item definition Product Sales • Recognises sales from territories where Group has lead commercialisation • Recognises supply of Beyfortus to Sanofi Alliance Revenue • Alliance Revenue comprises income ari
Slide 30: AstraZeneca P&L
APPEN DI X | P&L definitions AstraZeneca P&L 2026 P&L modelling considerations P&L line P&L Total Revenue • Expected to grow by a mid-to-high single digit percentage at CER (guidance) Gross margin • Core gross margin expected to be stable to slightly better vs. 2025 R&D • Core R&D expenses expected
Slide 31: AstraZeneca in non-small cell lung cancer
APPEN DI X | Oncology tumour maps AstraZeneca in non-small cell lung cancer Resectable Unresectable Metastatic Stg. I Stg. II-III Stg. I-II Stg. III 1L 2L 3L+ Est. epi (G7, 2025) ~150K ~70K ~50K ~100K ~310K ~190K ~70K CRT → Imfinzi Imfinzi + Imjudo + CTx POSEIDON PACIFIC Datroway + IO ± platinum TL0
Slide 32: AstraZeneca in breast cancer
APPEN DI X | Oncology tumour maps AstraZeneca in breast cancer Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7, 2025) 540k 135k 100k 75k 60k HER2-positive Enhertu → THP NST→ residual disease → Enhertu Enhertu ± pertuzumab Enhertu Enhertu 15-20% DESTINY-Breast
Slide 33: AstraZeneca in gastric cancer
APPEN DI X | Oncology tumour maps AstraZeneca in gastric cancer Early Advanced/Metastatic Stage II/III 1st line 2nd line 3rd line Est. epi (G7, 2025) 50k 90k 60k 30k Enhertu + rilvegostomig + FP HER2-positive ARTEMIDE-Gastric01 Enhertu Enhertu 20% DESTINY-Gastric02, 04 DESTINY-Gastric01 Enhertu + pe
Slide 34: AstraZeneca in bladder cancer
APPEN DI X | Oncology tumour maps AstraZeneca in bladder cancer High-risk NMIBC MIBC 1L mUC 96k 68k 46k Neoadjuvant Imfinzi + CTx → adjuvant Imfinzi NIAGARA cis-eligible ~50% Imfinzi + BCG induction and maintenance Imfinzi + CTx ± Imjudo POTOMAC NILE Neoadjuvant Imfinzi + enfortumab vedotin ± Imjudo
Slide 35: Oncology
APPEN DI X | Product Revenue Performance Oncology Tagrisso Lynparza 6% growth at CER to $3,775m in H1 2026 1% decrease at CER to $1,610m in H1 2026 1,000 2,500 900 800 2,000 700 Product Revenue ($m) Product Revenue ($m) 600 1,500 500 1,000 400 300 500 200 100 0 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q2 Q3 Q4
Slide 36: Oncology
APPEN DI X | Product Revenue Performance Oncology Imfinzi Imjudo 29% growth at CER to $3,548m in H1 2026 7% decrease at CER to $160m in H1 2026 2,000 100 1,800 90 1,600 80 1,400 70 Product Revenue ($m) Product Revenue ($m) 1,200 60 1,000 50 800 40 600 30 400 20 200 10 0 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Slide 37: Oncology
APPEN DI X | Product Revenue Performance Oncology Calquence Enhertu 16% growth at CER to $1,944m in H1 2026 32% growth at CER to $1,719m in H1 2026 1,200 1,000 900 1,000 800 700 800 Product Revenue ($m) Product Revenue ($m) 600 600 500 400 400 300 200 200 100 0 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q2 Q3 Q4
Slide 38: BioPharmaceuticals: Respiratory & Immunology
APPEN DI X | Product Revenue Performance BioPharmaceuticals: Respiratory & Immunology Fasenra Tezspire Saphnelo 12% growth at CER to $1,053m in H1 2026 40% growth at CER to $694m in H1 2026 24% growth at CER to $380m in H1 2026 600 450 250 400 500 350 200 400 300 Product Revenue ($m) Product Revenue
Slide 39: BioPharmaceuticals: Respiratory & Immunology
APPEN DI X | Product Revenue Performance BioPharmaceuticals: Respiratory & Immunology Breztri Symbicort 17% growth at CER to $699m in H1 2026 4% decrease at CER to $1,418m in H1 2026 400 800 350 700 300 600 Product Revenue ($m) Product Revenue ($m) 250 500 200 400 150 300 100 200 50 100 0 0 Q2 Q3 Q4
Slide 40: BioPharmaceuticals: Cardiovascular, Renal & Metabolism
APPEN DI X | Product Revenue Performance BioPharmaceuticals: Cardiovascular, Renal & Metabolism Farxiga Brilinta Lokelma 11% decrease at CER to $3,998m in H1 2026 66% decrease at CER to $186m in H1 2026 26% growth at CER to $419m in H1 2026 2,500 400 250 350 2,000 200 300 Product Revenue ($m) Produc
Slide 41: Rare Disease
APPEN DI X | Product Revenue Performance Rare Disease Ultomiris Strensiq Koselugo 14% growth at CER to $2,584m in H1 2026 40% growth at CER to $1,053m in H1 2026 21% growth at CER to $347m in H1 2026 1,400 600 250 1,200 500 200 1,000 400 Product Revenue ($m) Product Revenue ($m) Product Revenue ($m)
Slide 42: Glossary
APPEN DI X | Glossary Glossary 1L, 2L, 3L first-, second-, third-line ERS European Respiratory Society NME new molecular entity ADA American Diabetes Association ESC European Society of Cardiology NMIBC non-muscle invasive bladder cancer ADC antibody-drug conjugate ESR1m estrogen receptor alpha-muta
Slide 43: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis